

## **Board Announcement – Appointment of new CEO**

1 September 2022

The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals. Christian Bell, Chairman of the Veryan Board said, “Nick has made a tremendous contribution to Veryan during the clinical development and commercialisation of the BioMimics 3D Vascular Stent System and the integration with Otsuka Medical Devices following its acquisition of Veryan in 2018. The management of Otsuka Medical Devices and the Veryan board wish to thank Nick for his unparalleled contribution and wish him all the best for his future.”

Chas Taylor, who led Veryan’s business from 2007 to 2019 and who has been serving as a non-executive director since stepping down as CEO, has agreed to assume the role of Interim CEO and will work with the Veryan Board and its experienced Executive Team to deliver on its next phase of development.